ED
EDIT.US Editas Medicine Inc
- Market cap
- USD 335M
- P/E
- -
- P/B
- 3.90x
- ROE
- -105.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is EDIT.US undervalued?
Graham numberThe Graham number of Editas Medicine Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Editas Medicine Inc fundamental analysis
No fundamental analysis for Editas Medicine Inc yet.
Editas Medicine Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-de…
Full company profileEditas Medicine Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Editas Medicine Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.05M | 13.7M | 31.9M | 20.5M | 90.7M | 25.5M | 19.7M | 78.1M | 32.3M | 40.5M | 33.4M |
| Gross Profit | -50.9M | -69.4M | -58.7M | -76.4M | 90.7M | 25.5M | 19.7M | 72.1M | -167M | 40.5M | 32.8M |
| Operating Income | -97.2M | -120M | -114M | -141M | -135M | -193M | -226M | -169M | -251M | -99.3M | -90.5M |
| EBITDA | -96.1M | -117M | -110M | -138M | -131M | -188M | -220M | -147M | -233M | -149M | -89.6M |
| Net Income | -97.2M | -120M | -110M | -134M | -109M | -185M | -204M | -153M | -237M | -160M | -88.8M |
| EPS | -3.02 | -2.98 | -2.33 | -2.68 | -1.87 | -2.74 | -2.98 | -2.02 | -2.88 | -1.80 | -0.58 |
| Balance Sheet | |||||||||||
| Total Assets | 229M | 373M | 420M | 509M | 573M | 677M | 514M | 499M | 342M | 187M | 219M |
| Total Liabilities | 94.6M | 165M | 184M | 246M | 179M | 124M | 154M | 150M | 207M | 159M | 135M |
| Shareholders' Equity | 135M | 208M | 236M | 262M | 394M | 554M | 361M | 349M | 134M | 27.3M | 84.5M |
| Cash & Short-term Investments | 185M | 329M | 369M | 457M | 402M | 500M | 344M | 323M | 270M | 147M | 190M |
| Total Debt | 45.1M | 40.9M | 45.2M | 29.1M | 26.1M | 26.4M | 43.9M | 48.5M | 35.0M | 76.7M | 13.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -49.9M | -9.42M | -45.7M | -40.7M | -180M | -164M | -177M | -132M | -210M | -165M | -98.4M |
| Capital Expenditure | 3.49M | 2.06M | 4.75M | 6.17M | 7.16M | 7.98M | 4.12M | 4.72M | 8.83M | 607K | 264K |
| Free Cash Flow | -53.4M | -11.5M | -50.5M | -46.8M | -187M | -172M | -181M | -137M | -219M | -166M | -98.7M |
| Ratios | |||||||||||
| ROE | -72.2% | -57.8% | -46.6% | -51.0% | -27.8% | -33.4% | -56.7% | -43.9% | -176.6% | -586.6% | -105.1% |
| ROA | -42.4% | -32.2% | -26.2% | -26.3% | -19.1% | -27.3% | -39.7% | -30.7% | -69.4% | -85.8% | -40.5% |
| Net Profit Margin | -1,605.5% | -876.5% | -344.3% | -651.4% | -120.6% | -724.7% | -1,036.7% | -196.1% | -733.7% | -395.0% | -265.5% |
| Debt to Equity | 0.34x | 0.20x | 0.19x | 0.11x | 0.07x | 0.05x | 0.12x | 0.14x | 0.26x | 2.81x | 0.16x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Editas Medicine Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 4.00K | 0.00 | - |
| 2017 | USD 11.0K | 0.00 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Editas Medicine Inc
- Insiders 1.12%
- Institutions 87.29%
- Public & others 11.59%
- Shares outstanding 154M
- Free float 116M
Top funds holding EDIT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 4.54M | 2.96% | +2.69% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 4.39M | 2.86% | -10.21% | Sep 2026 |
| iShares Russell 2000 ETF | 3.99M | 2.60% | 0.00% | Oct 2026 |
| Vanguard Strategic Equity Inv | 2.03M | 1.32% | 0.00% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 1.31M | 0.85% | -0.38% | Oct 2026 |
| Fidelity Small Cap Index | 1.15M | 0.75% | +5.38% | Aug 2026 |
| iShares Biotechnology ETF | 1.08M | 0.70% | -0.19% | Oct 2026 |
| Selectra J. Lamarck Biotech A | 1.00M | 0.65% | 0.00% | Oct 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 927K | 0.60% | +123.14% | Sep 2026 |
| Vanguard Russell 2000 ETF | 913K | 0.59% | +58.42% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 698K | 0.45% | +0.24% | Oct 2026 |
| JPM Thmtcs Gentc Thrps C2 dist USD | 643K | 0.42% | -0.83% | Sep 2026 |
| Fidelity Extended Market Index | 636K | 0.41% | +22.41% | Sep 2026 |
| iShares Micro-Cap ETF | 475K | 0.31% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 436K | 0.28% | +0.11% | Sep 2026 |
| Schwab Small Cap Index | 381K | 0.25% | +56.37% | Sep 2026 |
| Fidelity Total Market Index | 318K | 0.21% | +82.64% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 289K | 0.19% | +55.83% | Sep 2026 |
| JPMorgan US Small Company L | 286K | 0.19% | 0.00% | Sep 2026 |
| BlackRock Advantage Small Cap Gr Instl | 270K | 0.18% | 0.00% | Sep 2026 |
Top institutions holding EDIT.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| TCG Crossover Management, LLC | 11.1M | 7.23% | 0.00% | Jun 2026 |
| BlackRock Inc | 10.6M | 6.90% | +14.32% | Jun 2026 |
| COMMODORE CAPITAL LP | 8.89M | 5.79% | 0.00% | Jun 2026 |
| RA Capital Management, LLC | 8.89M | 5.79% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 8.89M | 5.79% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.14M | 4.00% | +46.07% | Jun 2026 |
| Paradigm Biocapital Advisors LP | 5.59M | 3.64% | 0.00% | Jun 2026 |
| Opaleye Management Inc | 3.86M | 2.51% | +100.41% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 3.60M | 2.34% | +14.28% | Jun 2026 |
| Woodline Partners LP | 3.56M | 2.32% | 0.00% | Jun 2026 |
| Vivo Capital, LLC | 3.56M | 2.31% | 0.00% | Jun 2026 |
| GordonMD Global Investments LP | 3.13M | 2.04% | 0.00% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.61M | 1.70% | +367.98% | Jun 2026 |
| Geode Capital Management, LLC | 2.57M | 1.67% | +11.13% | Jun 2026 |
| Renaissance Technologies Corp | 2.47M | 1.61% | -37.84% | Jun 2026 |
| Logos Global Management LP | 2.22M | 1.45% | 0.00% | Jun 2026 |
| State Street Corp | 2.19M | 1.43% | +5.57% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 2.04M | 1.33% | +868.72% | Jun 2026 |
| D. E. Shaw & Co LP | 1.90M | 1.24% | -2.21% | Jun 2026 |
| JPMorgan Chase & Co | 1.86M | 1.21% | -4.36% | Jun 2026 |
Editas Medicine Inc company profile
- Company name
- Editas Medicine Inc
- Ticker
- EDIT.US
- Exchange
- USA Stocks
- Listed since
- Feb 3, 2016
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 87
- Fiscal year end
- December
- Address
- 11 Hurley Street, Cambridge, MA, United States, 02141
- Phone
- 617 401 9000
- Website
- editasmedicine.com
About Editas Medicine Inc
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Editas Medicine Inc management
10- Dr. Gilmore O'Neill M.D.President, CEO & Director · born 1964
- Ms. Amy ParisonSenior VP & CFO · born 1986
- Dr. Linda C. Burkly Ph.D.Executive VP & Chief Scientific Officer · born 1957
- Dr. Feng Zhang Ph.D.Co-Founder & Scientific Advisory Board Member
- Dr. George McDonald Church Ph.D.Co-Founder & Scientific Advisory Board Member · born 1954
- Mr. Gregory WhiteheadExecutive VP and Chief Technical & Quality Officer
- Mr. Damien Grierson J.D.Senior VP, General Counsel & Corporate Secretary
- Mr. Tom LoveVice President of People
- Mr. Frank PanaccioSenior VP & Chief Business Officer
- Ms. Brieana BuckleySenior Vice President of Development and Program Leadership